Baseline demographic data and key characteristics of Parkinson’s disease
| Treatment group | |||
|---|---|---|---|
| Placebo | Tolcapone | ||
| 100 mg tid | 200 mg tid | ||
| Patients | |||
| Number | 58 | 60 | 59 |
| Male:female ratio (%) | 60:40 | 52:48 | 56:44 |
| Age (y) | 64 (8) | 62 (10) | 63 (9) |
| Disease duration (y) | 10.5 (5.5) | 9.0 (5.0) | 10.0 (4.8) |
| Total daily levodopa dose (mg) | 660.5 (46.6) | 667.5 (41.5) | 675.8 (42.4) |
| Duration of levodopa treatment (y) | 9.0 (5.1) | 8.0 (5.1) | 9.0 (4.5) |
| Hoehn and Yahr stage | |||
| “On” (patient %) | |||
| 0-1.5 | 16 | 15 | 7 |
| 2 | 24 | 37 | 44 |
| 2.5 | 22 | 17 | 12 |
| 3-4 | 38 | 31 | 37 |
| “Off” (patient %) | |||
| 1-1.5 | 2 | 6 | 3 |
| 2 | 2 | 7 | 2 |
| 2.5 | 12 | 15 | 10 |
| 3-5 | 84 | 71 | 85 |
| UPDRS total score | 35.5 (18.1) | 33.4 (16.7) | 33.9 (18.0) |
Where applicable, data are means (SD); tid = three times daily; UPDRS = unified Parkinson’s disease rating scale.